CADL vs. SNDX, BGM, WVE, MLYS, ETNB, COLL, DYN, ELVN, RCUS, and CMRX
Should you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include Syndax Pharmaceuticals (SNDX), Qilian International Holding Group (BGM), Wave Life Sciences (WVE), Mineralys Therapeutics (MLYS), 89bio (ETNB), Collegium Pharmaceutical (COLL), Dyne Therapeutics (DYN), Enliven Therapeutics (ELVN), Arcus Biosciences (RCUS), and Chimerix (CMRX). These companies are all part of the "pharmaceutical products" industry.
Candel Therapeutics vs.
Syndax Pharmaceuticals (NASDAQ:SNDX) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, community ranking, dividends, analyst recommendations, profitability and media sentiment.
In the previous week, Syndax Pharmaceuticals had 1 more articles in the media than Candel Therapeutics. MarketBeat recorded 4 mentions for Syndax Pharmaceuticals and 3 mentions for Candel Therapeutics. Syndax Pharmaceuticals' average media sentiment score of 1.31 beat Candel Therapeutics' score of 0.64 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.
Candel Therapeutics has lower revenue, but higher earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Syndax Pharmaceuticals' return on equity of -64.34% beat Candel Therapeutics' return on equity.
Syndax Pharmaceuticals presently has a consensus target price of $36.20, indicating a potential upside of 214.65%. Candel Therapeutics has a consensus target price of $21.00, indicating a potential upside of 359.52%. Given Candel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Candel Therapeutics is more favorable than Syndax Pharmaceuticals.
Syndax Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -0.95, indicating that its stock price is 195% less volatile than the S&P 500.
Syndax Pharmaceuticals received 374 more outperform votes than Candel Therapeutics when rated by MarketBeat users. However, 68.00% of users gave Candel Therapeutics an outperform vote while only 65.38% of users gave Syndax Pharmaceuticals an outperform vote.
13.9% of Candel Therapeutics shares are owned by institutional investors. 4.1% of Syndax Pharmaceuticals shares are owned by insiders. Comparatively, 41.6% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Candel Therapeutics beats Syndax Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Candel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Candel Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CADL) was last updated on 4/20/2025 by MarketBeat.com Staff
Buy CADL Stock Free CADL Stock Alerts